Clinical Trial

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Study acronym: FRUITION
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-19; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2025-12-18
Trial Details
NCT Number NCT06992258
Lead Sponsor Criterium, Inc.
Conditions Colorectal Cancer
Enrollment 120 participants
Start Date 2025-10-27
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-17